ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Two Asian pharmas hold key for global supply of Oxford vaccine

India's Serum aims for 400m doses in 2020; S Korea's SK Bioscience keen on exports

Oxford University and AstraZeneca are tying up with Asian companies for mass production of the Oxford vaccine, which this photo shows being injected into a trial participant's arm. (Photo courtesy of Oxford University via AP)

MUMBAI/SEOUL -- Two Asian pharmaceutical companies are poised to become key players in the global fight against the new coronavirus pandemic after they were tapped to help mass-produce a promising new vaccine for the disease, which has already killed 650,000 worldwide and infected over 16 million.

Serum Institute of India and South Korea's SK Bioscience have reached an agreement to produce a vaccine developed by Oxford University and British pharmaceutical group AstraZeneca. The vaccine showed a robust immune response in its early trial phases during which it was tested on 1,077 participants, according to findings published in The Lancet medical journal on July 20.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more